William F. Kaemmerer
William F. Kaemmerer has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Andrew I. Schwebel
Ohio State University
1 shared publication- Richard Grondin
Department of Neuroscience, University of Kentucky Medical Center, Lexington, KY 40536, USA
1 shared publication Saul M. Siegel
1 shared publication
Latest Publications
- Open Access
- 1 March 2019
- Published by Taylor & Francis in Degenerative Neurological and Neuromuscular Disease
- Vol. ume 9, 3-17
The effects of huntingtin-lowering: what do we know so far?
Therapies targeting mutant huntingtin DNA, mRNA, and protein have a chance at becoming the first disease-modifying treatments for Huntington’s disease, a fatal inherited neurodegenerative disorder for which only symptom management treatments are available today. This review focuses on evidence addressing several key questions pertinent to huntingtin-lowering, ranging from the functions of wild-type huntingtin (wtHTT) that may be disrupted by huntingtin-lowering treatments through the various ways huntingtin can be lowered, the tolerability of wtHTT-lowering in mice and primates, what has been found in the Ionis Pharmaceutical safety trial of a huntingtin-lowering therapy, and to the question of how much mutant huntingtin may need to be lowered for a therapy to be clinically effective. We conclude that adverse consequences of lowering wtHTT in animals appear to be brain region-specific, and/or dependent upon the animal’s stage of development and the amount by which huntingtin is lowered. Therefore, safe approaches to huntingtin-lowering in patients may be to lower huntingtin only moderately, or lower huntingtin only in the most affected brain regions, or lower huntingtin allele-selectively, or all of the above. Many additional questions about huntingtin-lowering remain open, and will only be answered by upcoming clinical trials, such as whether the delivery approaches currently planned will be adequate to get the treatment to the necessary brain regions, and whether non-allele-selective huntingtin-lowering will be safe in the long run. Meantime, there is a role for preclinical research to address key knowledge gaps, including the effects of non-allele-selective huntingtin-lowering on protein trafficking and viability at the cellular level, the tolerability of wtHTT-lowering in the corticostriatal connections of the primate brain, and the effects of this lowering on the functioning of neurotransmitter systems and the transport of neurotrophic factors to the striatum.
- 1 March 2019
- Published by Taylor & Francis in Degenerative Neurological and Neuromuscular Disease
- Vol. ume 9, 3-17
Open AccessThe effects of huntingtin-lowering: what do we know so far?
Therapies targeting mutant huntingtin DNA, mRNA, and protein have a chance at becoming the first disease-modifying treatments for Huntington’s disease, a fatal inherited neurodegenerative disorder for which only symptom management treatments are available today. This review focuses on evidence addressing several key questions pertinent to huntingtin-lowering, ranging from the functions of wild-type huntingtin (wtHTT) that may be disrupted by huntingtin-lowering treatments through the various ways huntingtin can be lowered, the tolerability of wtHTT-lowering in mice and primates, what has been found in the Ionis Pharmaceutical safety trial of a huntingtin-lowering therapy, and to the question of how much mutant huntingtin may need to be lowered for a therapy to be clinically effective. We conclude that adverse consequences of lowering wtHTT in animals appear to be brain region-specific, and/or dependent upon the animal’s stage of development and the amount by which huntingtin is lowered. Therefore, safe approaches to huntingtin-lowering in patients may be to lower huntingtin only moderately, or lower huntingtin only in the most affected brain regions, or lower huntingtin allele-selectively, or all of the above. Many additional questions about huntingtin-lowering remain open, and will only be answered by upcoming clinical trials, such as whether the delivery approaches currently planned will be adequate to get the treatment to the necessary brain regions, and whether non-allele-selective huntingtin-lowering will be safe in the long run. Meantime, there is a role for preclinical research to address key knowledge gaps, including the effects of non-allele-selective huntingtin-lowering on protein trafficking and viability at the cellular level, the tolerability of wtHTT-lowering in the corticostriatal connections of the primate brain, and the effects of this lowering on the functioning of neurotransmitter systems and the transport of neurotrophic factors to the striatum.
- Open Access
- 20 April 2018
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 3 (2) , 166-177
How will the field of gene therapy survive its success?
In August 2017, for the first time, a gene therapy was approved for market release in the United States. That approval was followed by two others before the end of the year. This article cites primary literature, review articles concerning particular biotechnologies, and press releases by the FDA and others in order to provide an overview of the current status of the field of gene therapy with respect to its translation into practice. Technical hurdles that have been overcome in the past decades are summarized, as are hurdles that need to be the subject of continued research. Then, some social and practical challenges are identified that must be overcome if the field of gene therapy, having survived past failures, is to achieve not only technical and clinical but also market success. One of these, the need for an expanded capacity for the manufacturing of viral vectors to be able to meet the needs of additional gene therapies that will be coming soon, is a challenge that the talents of current and future bioengineers may help address.
- 20 April 2018
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 3 (2) , 166-177
Open AccessHow will the field of gene therapy survive its success?
In August 2017, for the first time, a gene therapy was approved for market release in the United States. That approval was followed by two others before the end of the year. This article cites primary literature, review articles concerning particular biotechnologies, and press releases by the FDA and others in order to provide an overview of the current status of the field of gene therapy with respect to its translation into practice. Technical hurdles that have been overcome in the past decades are summarized, as are hurdles that need to be the subject of continued research. Then, some social and practical challenges are identified that must be overcome if the field of gene therapy, having survived past failures, is to achieve not only technical and clinical but also market success. One of these, the need for an expanded capacity for the manufacturing of viral vectors to be able to meet the needs of additional gene therapies that will be coming soon, is a challenge that the talents of current and future bioengineers may help address.
- 1 January 2017
- Published by Cambridge University Press (CUP)
- p. 169-180
Optogenetics for Neurological Disorders: What Is the Path to the Clinic?
- 1 January 2017
- Published by Cambridge University Press (CUP)
- p. 169-180
Optogenetics for Neurological Disorders: What Is the Path to the Clinic?
- 1 January 1978
- Published by American Psychological Association (APA)
Siegel Scale of Support for Innovation
- 1 January 1978
- Published by American Psychological Association (APA)
Siegel Scale of Support for Innovation
- 1 August 1976
- Published by SAGE Publications in Psychological Reports
- Vol. 39 (1) , 107-114
Factors of the Rotter Internal-External Scale
Previous investigators have reported that the Rotter I-E scale (1966) may measure many dimensions rather than a unidimensional trait. Following Collins (1974), each of the 23 forced-choice internal and external alternatives of the I-E scale were separated and administered as 46 Likert-scale items. The Likert-format administration was equivalent to the original method. Principal factors analysis and varimax rotation yielded five factors: belief in a nonrational world, belief in a politically unresponsive world, belief in a predictable world, belief in a just world, and belief in the meaningfulness of personal effort. These factors are similar to those reported by Collins.
- 1 August 1976
- Published by SAGE Publications in Psychological Reports
- Vol. 39 (1) , 107-114
Factors of the Rotter Internal-External Scale
Previous investigators have reported that the Rotter I-E scale (1966) may measure many dimensions rather than a unidimensional trait. Following Collins (1974), each of the 23 forced-choice internal and external alternatives of the I-E scale were separated and administered as 46 Likert-scale items. The Likert-format administration was equivalent to the original method. Principal factors analysis and varimax rotation yielded five factors: belief in a nonrational world, belief in a politically unresponsive world, belief in a predictable world, belief in a just world, and belief in the meaningfulness of personal effort. These factors are similar to those reported by Collins.